CDTTW
Conduit Pharmaceuticals Inc.NASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.57
52W High
$0.02
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for oncology and autoimmune disorders, addressing critical unmet medical needs. With its proprietary drug delivery platforms and a promising pipeline, the company aims to translate cutting-edge scientific research into effective clinical solutions that enhance patient outcomes. Conduit's strategic partnerships bolster its potential for treatment advancements, positioning it as a compelling investment opportunity in the rapidly evolving biotech landscape, especially as it continues to progress through key clinical trial phases.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-24.74M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -345.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-77.82 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $2.55M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
242.31%
HV 20-Day
248.76%
HV 30-Day
223.40%
HV 60-Day
183.88%
HV Rank
—
Volatility is currently expanding
Data last updated: 5/5/2026